Ibrutinib Capsules (Imbruvica) are an advanced targeted therapy used in the treatment of various blood cancers, including Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma. Belonging to the class of Bruton’s Tyrosine Kinase (BTK) inhibitors, this medication works by blocking a specific protein essential for the growth and survival of malignant B-cells, thereby slowing disease progression and promoting cancer cell death. Taken orally once daily, Ibrutinib offers a convenient and effective alternative to traditional chemotherapy, especially for patients with relapsed or resistant conditions. It is generally well-tolerated but may cause side effects such as diarrhea, fatigue, infections, or bleeding risks, making regular medical monitoring essential. With its targeted mechanism and proven efficacy, Ibrutinib has become a key option in modern hematology for improving patient outcomes and long-term disease management.
Reviews
There are no reviews yet.